Lumida
/ACNT
⌘K
Ascent Industries Co

Ascent Industries Co

ACNT
$15.00USD+1.49%+0.22 today

MARKET CAP

135.1M

P/E (TTM)

136.4x

FWD P/E

DAY RANGE

$15 – $15

52W RANGE

$12
$18

AI Summary

Stalk
StalkMedium

ACNT remains in Stage 2 – Advancing (Corrective Reset) with a bullish medium-term bias, supported by the long-term uptrend and price holding above key moving averages. The active Bearish Pivot Point signals potential downside repair, and price is currently below flattening EMAs, making immediate entry unfavorable. Buy-side engagement should be deferred to pullbacks into the repaired 9/21 EMA zone or near consolidation lows. Key risks include a decisive break below the 200 DMA or consolidation support, which would invalidate the bullish posture.

  • Q2 net sales rose 37.6% YoY to $25.7M on 15.2% volume growth
  • Adjusted EBITDA turned positive at $1.5M versus $300K loss year-ago
  • Gross margin declined to 21.6% from 26.1% on higher input costs
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Ascent Industries Co. (NASDAQ: ASC) is an established player in the specialty chemicals sector, specializing in the development, production, and distribution of chemical ingredients and process aids for industries such as oil & gas, personal care, automotive, and construction. With a strong heritage since its founding in 1945 and a name change from Synalloy Corporation in August 2022, Ascent focuses on growth through strategic acquisitions and operational excellence while facing challenges from rising input costs and market competition.

Bull says

  • Q2 net sales rose 37.6% YoY to $25.7M on 15.2% volume growth
  • Adjusted EBITDA turned positive at $1.5M versus $300K loss year-ago
  • Midwest Graphic acquisition secured first new customer, boosting operational synergies
  • Management targets $3–5M annualized gross profit uplift via efficiency measures
  • Existing customers account for 73% of project wins, showing strong retention
  • Positive rate sensitivity suggests rising interest rates could boost profitability

Bear says

  • Gross margin declined to 21.6% from 26.1% on higher input costs
  • Cash position $28.1M, cash conversion cycle 75 days signals working capital strain
  • Seasonal program turnover in legacy business may cause Q1/Q4 revenue dips
  • Geopolitical tensions and raw material inflation threaten further margin compression
  • Weak earnings yield and low book-to-price metrics signal valuation concerns
  • Analyst downgrades and negative revision trends reflect bearish sentiment

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-14-2025neutral

Transcript signals

Bull points

  • Despite ongoing market headwinds, the team delivered both sequential and year-over-year bottom-line improvements. Overall, momentum is building within the Tubular segment and we expect our initial efforts related to product mix optimization to have a meaningful impact on our segment level adjusted EBITDA in the near future and will be at full run rate in the second half of 2024.
  • momentum is building within Tubular.
  • Our demonstrated ability to innovate at the speed of our customers is one of our competitive advantages. To give you some color on that, one of our prospective customers expressed a need late March. Within one week, our team had developed several different product formulations with complex multi-step reactions. Samples were immediately shipped. Once received, our prospective customer tested those samples and later advised that one of our products had been qualified. As a result of that, we have received a customer commitment for over £3 million, translating to over $6 million of revenue on an annualized basis.

Bear points

  • we continue to experience challenges associated with inventory destocking and soft market demand in the first quarter.
  • the full impact of these efforts were muted by soft demand.
  • our strategic sourcing team delivered double-digit unit material cost reduction, and we have yet to see the full run rate of that impact of their ongoing efforts hit the P&L.
Read full transcript analysis ›